The positive response of BRCA-mutated breast and ovarian cancers to PARP inhibitors [42,43] has raised interest in identifying additional determinants of PARP inhibitor sensitivity, thereby extending the utility of PARP inhibitors in cancer therapy [39]. This evidence concerns the gene PARP1 and ovarian cancer.